Pharmaceutical giant Novo Nordisk recently conducted a large-scale study investigating whether weight-loss drug semaglutide could slow Alzheimer’s progression. Unfortunately, the study was unsuccessful, and the trial was halted early. However, although more research is needed, the results are not entirely negative.